Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I

2021271 citationsJournal Articlehybrid Open Access

Authors

Kathleen N. Moore · University of Oklahoma Health Sciences Center

Amit M. Oza · Princess Margaret Cancer Centre

Nicoletta Colombo · European Institute of Oncology

Ana Oaknin · Vall d'Hebron Institute of Oncology

Giovanni Scambia · Istituti di Ricovero e Cura a Carattere Scientifico

Domenica Lorusso · Fondazione IRCCS Istituto Nazionale dei Tumori

Gottfried E. Konecny

Abstract

In patients with platinum-resistant EOC, MIRV did not result in a significant improvement in PFS compared with chemotherapy. Secondary endpoints consistently favored MIRV, particularly in patients with high FRα expression. MIRV showed a differentiated and more manageable safety profile than chemotherapy.

Topics & Keywords

Ovarian cancer diagnosis and treatment PARP inhibition in cancer therapy HER2/EGFR in Cancer Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Annals of Oncology

Volume 32, Issue 6, pp. 757-765

DOI: 10.1016/j.annonc.2021.02.017

Field-Weighted Citation Impact: 35.64